EW · 10-Q · 2026Q2 · Full report

Liquidity and Debt Position

Edwards Lifesciences Corp · 2026-08-04 · Importance 49 · Surprise 6

At June 30, 2026, Edwards held $3.7 billion of cash and cash equivalents and $540.5 million of short-term investments across the United States and foreign locations. The company had no borrowings under its $750.0 million unsecured multi-currency revolving credit facility, which matures July 15, 2027 and can be increased by up to $250.0 million subject to lender agreement. Edwards’ outstanding 2018 senior notes had a $598.7 million carrying value and bear a fixed 4.3% interest rate through their June 15, 2028 maturity. Management stated that available liquidity sources were sufficient for working capital, capital expenditures, and other financial commitments.

Key facts

• Edwards has a five-year Credit Agreement providing for a $750.0 million unsecured revolving credit facility that matures on July 15, 2027, with an option to increase by up to $250.0 million and extend maturity by one year subject to lender agreement; as of June 30, 2026, no amounts were outstanding under the Credit Agreement. source
• As of June 30, 2026, cash and cash equivalents and short-term investments held in the United States were $3.7 billion and outside the United States were $540.5 million. source
• In June 2018 Edwards issued $600.0 million of 4.3% fixed-rate unsecured senior notes due June 15, 2028; as of June 30, 2026 the carrying value was $598.7 million. source